Stents, Drug Eluting

Patients who took dual antiplatelet therapy medications beyond the standard 12 months after coronary stent placement were significantly less likely to develop blood clots within their stents or to have a heart attack than those whose treatment fol...

bioresorbable stents, dissolving stents

A key prediction for interventional cardiology coming out of recent Transcatheter Cardiovascular Therapeutics (TCT) and American College of Cardiology (ACC) meetings is that bioresorbable stents will eventually replace conventional metallic stents...

Boston Scientific Corporation has received U.S. Food and Drug Administration (FDA) approval for the Promus Premier Everolimus-Eluting Platinum Chromium Coronary Stent System, the company's durable polymer ...

InspireMD, MGuard, CGuard, drug-eluting stent, MASTER II, CARENET, trials
InspireMD, Inc. announced results from two important clinical trials. Thirty-day results from the MASTER II trial, which enrolled 310 of a planned 1,114...
bioresorbable stents
Ongoing clinical trials of bioresorbable stents continue to show positive data for the devices, which are widely expected to overtake metallic stents in the...
Boston Scientific, EVOLVE II, Synergy, bioresorbable stent
In the first successful United States trial of a bioabsorbable polymer stent, the Boston Scientific Synergy everolimus-eluting bioabsorbable polymer platinum...
stents, Cobra, celonova
CeloNova BioSciences, Inc., announced that positive first-in-man (FIM) clinical trial results found its Cobra PzF coronary stent system with an advanced nano-...
The Abbott family of Xience everolimus-eluting coronary stents—including the Xience V, Xience nano, Xience Prime, Xience Xpedition, and
MicroVention Inc.’s Low-Profile Visualized Intraluminal Support Device (LVIS and LVIS Jr.) is a stent and delivery system used to...
Boston Scientific received U.S. Food and Drug Administration (FDA) approval for the Rebel platinum chromium coronary stent system, the...

Articles

bioresorbable stents
Ongoing clinical trials of bioresorbable stents continue to show positive data for the devices, which are widely expected to overtake metallic stents in the...
DAPT study
Patients who took dual antiplatelet therapy medications beyond the standard 12 months after coronary stent placement were significantly less likely to develop...
bioresorbable stents, dissolving stents, Absorb stent, BVS
A key prediction for interventional cardiology coming out of recent Transcatheter Cardiovascular Therapeutics (TCT) and American College of Cardiology (ACC)...
A big fly in the ointment for widespread adoption of many new technologies is cost. In today’s cost-conscience environment of healthcare reform, there needs to...

Video Center

The silence is deafening. And since radiology associations, physician groups and vendors have yet...
18 hours 21 min ago
The America College of Cardiology has released its list of key late-breaking clinical trials at the...
1 week 1 day ago
As editor of DAIC, I keep a close watch on trends in cardiovascular technology and try to predict...
4 weeks 1 day ago
The webinar "State of the Art in MRI Pediatric Brain Perfusion Imaging" educates participants about the state of the art clinical and emerging translational...
This webinar discusses why contemporary adult cardiac interventions require significant ionizing radiation with potential health risks to both the patient and...
This webinar explained the benefits of better access, productivity and revenue cycle efficiency in a modern cardiovascular information system (CVIS...